Search Within

Center for Pancreatic Cancer Research

Formats
  1. Journal Article (5064)
  2. Meeting Abstract (2483)
  3. Book Section (225)
  4. Review (221)
  5. Editorial (135)
  6. Conference Paper (75)
  7. Correspondence (48)
  8. Research Letter (43)
  9. Miscellaneous (41)
  10. Guidelines (38)
  11. Book Whole (20)
Groups
  1. Department of Medicine (3946)
  2. Solid Tumor Oncology Division (3243)
  3. Surgery (3170)
  4. GSK Faculty (2916)
  5. Epidemiology and Biostatistics (2527)
  6. Gastrointestinal Oncology Service (2298)

More Groups

People
  1. Mithat Gonen (1036)
  2. William Jarnagin (913)
  3. Eileen O'Reilly (795)
  4. Michael D'Angelica (789)
  5. T Peter Kingham (622)
  6. David Kelsen (538)

More People

Years
  1. 2025 (294)
  2. 2024 (497)
  3. 2023 (523)
  4. 2022 (602)
  5. 2021 (555)
  6. 2020 (562)

More Years

Publications
  1. Journal of Clinical Oncology (927)
  2. Annals of Surgical Oncology (397)
  3. Cancer Research (226)
  4. International Journal of Radiation Oncology, Biology, Physics (219)
  5. Laboratory Investigation (209)
  6. Modern Pathology (191)

More Publications

Publishers
  1. American Society of Clinical Oncology (1003)
  2. Springer (842)
  3. Elsevier Inc. (757)
  4. Nature Publishing Group (633)
  5. American Association for Cancer Research (551)
  6. Elsevier Science, Inc. (510)

More Publishers

Results (8393)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Population-based, real-world prognostic factors related to survival among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Meeting Abstract

    Yu, K. H.; Cockrum, P.; Surinach, A.; Wang, S.; Chu, B. C.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer
    Meeting Abstract

    Shiu, K. K.; Andre, T.; Kim, T. W.; Jensen, B. V.; Jensen, L. H.; Punt, C. J. A.; Smith, D. M.; Garcia-Carbonero, R.; Benavides, M.; Gibbs, P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC)
    Meeting Abstract

    Schwartz, L. H.; Kindler, H. L.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer
    Meeting Abstract

    Romesser, P. B.; Holliday, E. B.; Philip, T.; Garcia-Carbonero, R.; Capdevila, J.; Tuli, R.; Sarholz, B.; Kuipers, M.; Rodriguez, A.; Diaz-Padilla, I.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas
    Meeting Abstract

    Katz, M. H. G.; Shi, Q.; Meyers, J. P.; Herman, J. M.; Choung, M.; Wolpin, B. M.; Ahmad, S.; de Wilton Marsh, R.; Schwartz, L. H.; Behr, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202
    Meeting Abstract

    Geyer, S. M.; Mahoney, M. R.; Asmis, T. R.; Hall, N.; Karovic, S.; Knopp, M. V.; Kumthekar, P.; Nixon, A. B.; O'Reilly, E. M.; Schwartz, L. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer
    Meeting Abstract

    Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance)
    Meeting Abstract

    Dercle, L.; Geyer, S. M.; Nixon, A. B.; Innocenti, F.; Shi, Q.; Jacobson, S. B.; Luk, L.; Liu, A.; Yang, H.; Wen, Y.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC)
    Meeting Abstract

    El Dika, I. H.; Geyer, S. M.; Nixon, A. B.; Innocenti, F.; Shi, Q.; Jacobson, S. B.; Yaqubie, A.; Lopez, J. C.; Huang, B. H.; Tang, Y. W.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Randomized phase II trial of olaparib + pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) mutations: SWOG S2001
    Meeting Abstract

    Chung, V.; Guthrie, K. A.; Pishvaian, M. J.; Lowy, A. M.; Chiorean, E. G.; Duong, M. T.; O'Reilly, E. M.; Philip, P. A.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save